Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NYSE:TARO

Taro Pharmaceutical Industries (TARO) Stock Price, News & Analysis

Taro Pharmaceutical Industries logo

About Taro Pharmaceutical Industries Stock (NYSE:TARO)

Advanced Chart

Key Stats

Today's Range
$42.97
$42.97
50-Day Range
$42.20
$42.99
52-Week Range
$32.67
$45.76
Volume
N/A
Average Volume
45,199 shs
Market Capitalization
$1.62 billion
P/E Ratio
29.84
Dividend Yield
N/A
Price Target
$43.00
Consensus Rating
Hold

Company Overview

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

Taro Pharmaceutical Industries Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
14th Percentile Overall Score

TARO MarketRank™: 

Taro Pharmaceutical Industries scored higher than 14% of companies evaluated by MarketBeat, and ranked 912th out of 955 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Taro Pharmaceutical Industries is 29.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 110.18.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Taro Pharmaceutical Industries is 29.84, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 88.26.

  • Price to Book Value per Share Ratio

    Taro Pharmaceutical Industries has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for TARO.
  • Dividend Yield

    Taro Pharmaceutical Industries does not currently pay a dividend.

  • Dividend Growth

    Taro Pharmaceutical Industries does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for TARO.
  • Search Interest

    3 people have searched for TARO on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Taro Pharmaceutical Industries insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.80% of the stock of Taro Pharmaceutical Industries is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    91.40% of the stock of Taro Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Taro Pharmaceutical Industries' insider trading history.
Receive TARO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TARO Stock News Headlines

Unlock the Secret to Microsoft's Yearly Gains
What would you do if you knew that you could have placed a trade on Microsoft every year on October 13th … And had the chance to pocket an impressive gain in a matter of days… And this didn’t work just once… Not twice… But it worked for an entire decade… According to market veteran Jack Carter’s research, the recurring phenomenon generated winner after winner for 10 straight years! All you had to do is wait for October 13th to roll around on the calendar… Then place a quick trade… Of course, we can’t promise profits or prevent losses… But you can get 10 FREE trade ideas from Jack, just like that one on Microsoft.
See More Headlines

TARO Stock Analysis - Frequently Asked Questions

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) issued its quarterly earnings data on Thursday, October, 28th. The company reported $0.66 EPS for the quarter, missing the consensus estimate of $1.02 by $0.36. The company earned $131.99 million during the quarter, compared to the consensus estimate of $153.23 million. Taro Pharmaceutical Industries had a net margin of 8.56% and a trailing twelve-month return on equity of 3.75%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Taro Pharmaceutical Industries investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
10/28/2021
Today
1/14/2025
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
1,554
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$43.00
High Stock Price Target
$43.00
Low Stock Price Target
$43.00
Potential Upside/Downside
+0.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$53.87 million
Pretax Margin
13.14%

Debt

Sales & Book Value

Annual Sales
$629.18 million
Cash Flow
$2.38 per share
Book Value
$47.70 per share

Miscellaneous

Free Float
32,400,000
Market Cap
$1.62 billion
Optionable
Optionable
Beta
0.56
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NYSE:TARO) was last updated on 1/15/2025 by MarketBeat.com Staff
From Our Partners